Terms: = Head and neck cancer AND FGFR4, CD334, 2264, ENSG00000160867, P22455, MGC20292, TKF, JTK2 AND Treatment
17 results:
1. Melatonin Suppresses Oral Squamous Cell Carcinomas Migration and Invasion through Blocking FGF19/FGFR 4 Signaling Pathway.
Wang L; Su Y; Choi WS
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576070
[TBL] [Abstract] [Full Text] [Related]
2. FGF19/fgfr4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis.
Lang L; Xiong Y; Prieto-Dominguez N; Loveless R; Jensen C; Shay C; Teng Y
J Exp Clin Cancer Res; 2021 Mar; 40(1):93. PubMed ID: 33691750
[TBL] [Abstract] [Full Text] [Related]
3. Chemo-resistant Gastric cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus.
Liu JB; Jian T; Yue C; Chen D; Chen W; Bao TT; Liu HX; Cao Y; Li WB; Yang Z; Hoffman RM; Yu C
Anticancer Res; 2019 Apr; 39(4):1689-1698. PubMed ID: 30952707
[TBL] [Abstract] [Full Text] [Related]
4. Blocking fgfr4 exerts distinct anti-tumorigenic effects in esophageal squamous cell carcinoma.
Xin Z; Song X; Jiang B; Gongsun X; Song L; Qin Q; Wang Q; Shi M; Liu X
Thorac Cancer; 2018 Dec; 9(12):1687-1698. PubMed ID: 30267473
[TBL] [Abstract] [Full Text] [Related]
5. treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract] [Full Text] [Related]
6. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract] [Full Text] [Related]
7. Lenvatinib in the Therapy of Aggressive Thyroid cancer: State of the Art and New Perspectives with Patents Recently Applied.
Ferrari SM; Ruffilli I; Centanni M; Virili C; Materazzi G; Alexopoulou M; Miccoli M; Antonelli A; Fallahi P
Recent Pat Anticancer Drug Discov; 2018; 13(2):201-208. PubMed ID: 29468981
[TBL] [Abstract] [Full Text] [Related]
8. A Multi-institutional Analysis of Trimodality Therapy for Esophageal cancer in Elderly Patients.
Lester SC; Lin SH; Chuong M; Bhooshan N; Liao Z; Arnett AL; James SE; Evans JD; Spears GM; Komaki R; Haddock MG; Mehta MP; Hallemeier CL; Merrell KW
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):820-828. PubMed ID: 28476435
[TBL] [Abstract] [Full Text] [Related]
9. Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report.
Giannetta E; Isidori AM; Durante C; Di Gioia C; Longo F; Tombolini V; Bulzonetti N; Graziadio C; Pofi R; Gianfrilli D; Verrienti A; Carletti R; Filetti S; Lenzi A; Baroli A
Medicine (Baltimore); 2017 Feb; 96(6):e5621. PubMed ID: 28178124
[TBL] [Abstract] [Full Text] [Related]
10. fgfr4 Is a Potential Predictive Biomarker in Oral and Oropharyngeal Squamous Cell Carcinoma.
Koole K; van Kempen PM; van Bockel LW; Smets T; van der Klooster Z; Dutman AC; Peeters T; Koole R; van Diest P; van Es RJ; Willems SM
Pathobiology; 2015; 82(6):280-9. PubMed ID: 26551585
[TBL] [Abstract] [Full Text] [Related]
11. The Prognostic Significance of fgfr4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy.
Shim HJ; Shin MH; Kim HN; Kim JH; Hwang JE; Bae WK; Chung IJ; Cho SH
Cancer Res Treat; 2016 Jan; 48(1):71-9. PubMed ID: 25989802
[TBL] [Abstract] [Full Text] [Related]
12. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.
Cabanillas ME; Schlumberger M; Jarzab B; Martins RG; Pacini F; Robinson B; McCaffrey JC; Shah MH; Bodenner DL; Topliss D; Andresen C; O'Brien JP; Ren M; Funahashi Y; Allison R; Elisei R; Newbold K; Licitra LF; Sherman SI; Ball DW
Cancer; 2015 Aug; 121(16):2749-56. PubMed ID: 25913680
[TBL] [Abstract] [Full Text] [Related]
13. The genomic landscape of oesophagogastric junctional adenocarcinoma.
Chong IY; Cunningham D; Barber LJ; Campbell J; Chen L; Kozarewa I; Fenwick K; Assiotis I; Guettler S; Garcia-Murillas I; Awan S; Lambros M; Starling N; Wotherspoon A; Stamp G; Gonzalez-de-Castro D; Benson M; Chau I; Hulkki S; Nohadani M; Eltahir Z; Lemnrau A; Orr N; Rao S; Lord CJ; Ashworth A
J Pathol; 2013 Nov; 231(3):301-10. PubMed ID: 24308032
[TBL] [Abstract] [Full Text] [Related]
14. Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients.
Farnebo L; Tiefenböck K; Ansell A; Thunell LK; Garvin S; Roberg K
Int J Cancer; 2013 Oct; 133(8):1994-2003. PubMed ID: 23564498
[TBL] [Abstract] [Full Text] [Related]
15. Validation of genetic sequence variants as prognostic factors in early-stage head and neck squamous cell cancer survival.
Azad AK; Bairati I; Samson E; Cheng D; Mirshams M; Qiu X; Savas S; Waldron J; Wang C; Goldstein D; Xu W; Meyer F; Liu G
Clin Cancer Res; 2012 Jan; 18(1):196-206. PubMed ID: 22076708
[TBL] [Abstract] [Full Text] [Related]
16. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
[TBL] [Abstract] [Full Text] [Related]
17. Dual inhibition of RET and fgfr4 restrains medullary thyroid cancer cell growth.
Ezzat S; Huang P; Dackiw A; Asa SL
Clin Cancer Res; 2005 Feb; 11(3):1336-41. PubMed ID: 15709206
[TBL] [Abstract] [Full Text] [Related]
